Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Safety and efficacy of different lanreotide doses for polycystic liver disease

This month's issue of the Alimentary Pharmacology & Therapeutics investigates the safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease.

News image

Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic liver diseases.

Animal studies that demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.

Dr Temmerman and colleagues from Belgium investigated the safety and efficacy of two different LAN doses in polycystic liver diseases patients.

The 6-month results of the LOCKCYST I trial, its extension study, and the LOCKCYST II trial were pooled.

Long-acting lanreotide at baseline and month 6 was measured by CT-scan and blindly re-analyzed by 2 independent radiologists.

Severe side effects with long-acting lanreotide 120 mg was 16%
Alimentary Pharmacology & Therapeutics

The study population consisted of 3 groups.

Each received treatment every 4 weeks during 6 months plus placebo, or long-acting lanreotide at 90 mg or 120 mg.

The team reported excellent inter-observer variability and agreement in the calculation of Long-acting lanreotide.

The researchers observed that severe side effects with placebo, long-acting lanreotide 90 mg and 120 mg were 0%, 7% and 16%, respectively.

Change in long-acting lanreotide after 6 months in these 3 groups included an increase of +36 mL, decrease of −82 mL, and decrease of -123 mL, respecitvely.

Based on ROC analysis, a reduction of 120 mL or more in liver volume has a positive predictive value of 64% for improving symptoms.

Dr Temmerman's team concludes, "Both long-acting lanreotide 90 mg and long-acting lanreotide120 mg reduce liver volume."

"Long-acting lanreotide 90 mg has less side effects. "

"This suggests that in case of intolerance to long-acting lanreotide 120 mg, a dose reduction to long-acting lanreotide 90 mg is meaningful."

Aliment Pharmacol Ther 2013: 38(4): 397406
06 August 2013

Go to top of page Email this page Email this page to a colleague

 04 September 2015

Advanced search
 04 September 2015 
HCV treatment in advanced liver disease
 04 September 2015 
IVF in women with IBD
 04 September 2015 
Crohn's disease of the esophagus
 03 September 2015 
Factors that influence GI transit with the wireless motility capsule
 03 September 2015 
Antibiotic resistance of H. pylori
 03 September 2015 
NAFLD in adolescents undergoing bariatric surgery
 02 September 2015 
Anxiety and functional dyspepsia
 02 September 2015 
Cancer predisposition genes in suspected Lynch syndrome
 02 September 2015 
Adherence to a gluten-free diet in celiac disease
 01 September 2015 
Nonceliac wheat sensitivity and autoimmune disease
 01 September 2015 
Dysphagia after antireflux surgery
 01 September 2015 
Predict treatment success in ulcerative colitis
 31 August 2015 

Fecal microbiota transplantation in IBD

 31 August 2015 
Probiotics and liver transplantation
 31 August 2015 
Cancer incidence in Barrett's
 28 August 2015 
Statin use and survival in pancreatic cancer
 28 August 2015 
Bacterial endotoxin and NAFLD
 28 August 2015 
Interferon-free regimens for Hep C
 27 August 2015 
HCV in Egypt
 27 August 2015 
Liver abnormalities in celiac disease
 27 August 2015 
Gene expression for hepatocellular carcinoma
 26 August 2015 
Medical management of diverticular disease
 26 August 2015 
Treatment of erosive esophagitis
 26 August 2015 
Dermatological complications of anti-TNF therapy in IBD
 25 August 2015 
Markers for colorectal cancer screening
 25 August 2015 
Long-term PPI use and serum gastrin levels
 25 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Cirrhosis in Hepatitis C patients
 24 August 2015 
Aspirin use and colorectal cancer survival
 21 August 2015 
Activity indexes in ulcerative colitis
 21 August 2015 
Coffee and gallstone disease
 21 August 2015 
Alcoholic cirrhosis in relapse after liver transplant
 20 August 2015 
Cirrhosis in the USA
 20 August 2015 
Mortality causes in liver cirrhosis
 20 August 2015 
Risk of death in IBD
 19 August 2015 
Predicting intestinal surgery in Crohn's disease
 19 August 2015 
Sleep positioning device reduces reflux
 19 August 2015 
Improved screening colonoscopy quality
 18 August 2015 
Health insurance influences HCV screening outcomes
 18 August 2015 
Somatostatin analogues in polycystic liver disease
 18 August 2015 
Global consensus report on H. pylori gastritis
 17 August 2015 
Biomarker of fibrosis stage in NAFLD
 17 August 2015 
Prognostic score for primary biliary cirrhosis
 17 August 2015 
Measuring subjective health in patients with IBS
 14 August 2015 
Factors that influence ulcerative colitis procedure type
 14 August 2015 
H. pylori in African American and Hispanic veterans
 14 August 2015 
Hep E virus in decompensated chronic liver disease
 13 August 2015 
H. pylori in drinking water
 13 August 2015 
Sofosbuvir-regimens in HCV
 13 August 2015 
IBS among Japanese adolescents
 12 August 2015 
Infliximab in patients in IBD
 12 August 2015 
Predictors of severity of IBD
 12 August 2015 
Peritoneal carcinomatosis in colorectal cancer
 11 August 2015 
Chemotherapy and intestinal microbiomes
 11 August 2015 
H. pylori and immune thrombocytopenic purpura
 11 August 2015 
Sexual dysfunction after rectal cancer treatment
 10 August 2015 
Predicting lymph node metastasis in T1 colorectal cancer
 10 August 2015 
Scoring systems to predict alcoholic hepatitis outcomes
 10 August 2015 
Sofosbuvir-based regimens in veterans with HCV

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us